Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies.

Abstract

PURPOSE:

Tadalafil once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia consistently shows statistically significant I-PSS improvements. However, physicians and patients wish to know whether tadalafil provides rapid, clinically meaningful improvement in lower urinary tract symptoms. In this post hoc analysis we integrated results from 4 placebo controlled studies to determine the duration of tadalafil once daily required to achieve clinically meaningful improvement.

MATERIALS AND METHODS:

We performed post hoc analysis of data integrated from 4 double-blind studies of tadalafil 5 mg and placebo once daily in 742 and 735 men, respectively, 45 years old or older with total I-PSS 13 or greater. Two clinically meaningful improvement categories were assessed, including 1) 3-point or greater baseline to end point total I-PSS improvement and 2) 25% or greater baseline to end point total I-PSS improvement. I-PSS was assessed at weeks 4, 8 and 12 in all studies, week 1 in 2 and week 2 in 1. Results in men treated with tadalafil who showed clinically meaningful improvement (responders) were further examined to determine the earliest time to clinically meaningful improvement.

RESULTS:

Of 742 tadalafil treated patients 513 (69.1%) and 444 (59.8%) demonstrated category 1 and 2 clinically meaningful improvement, respectively, at the study end point. Of 234 category 1 responders with week 1 assessments 140 (59.8%) achieved clinically meaningful improvement by week 1 and 407 of the total of 513 category 1 responders (79.3%) showed it by week 4. Of the 205 category 2 responders with week 1 assessments 103 (50.2%) achieved clinically meaningful improvement by week 1 while 322 of the 444 category 2 responders (72.5%) did so by week 4.

CONCLUSIONS:

Tadalafil 5 mg once daily led to clinically meaningful improvement in approximately two-thirds of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. More than half of this group of tadalafil treated responders achieved clinically meaningful improvement after 1 week of therapy and more than 70% did so within 4 weeks.

• Authors: Matthias Oelke, Rajesh Shinghal, Angelina Sontag, Simin K Baygani, Craig F Donatucci
• Journal: The Journal of urology (J Urol) Vol. 193 Issue 5 Pg. 1581-9 (May 2015) ISSN: 1527-3792 [Electronic] United States
• PMID: 25437533 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Chemical References

• Carbolines
• Phosphodiesterase 5 Inhibitors
• Tadalafil

Topics

• Carbolines (administration & dosage)
• Double-Blind Method
• Drug Administration Schedule
• Humans
• Lower Urinary Tract Symptoms (drug therapy, etiology)
• Male
• Middle Aged
• Phosphodiesterase 5 Inhibitors (administration & dosage)
• Prostatic Hyperplasia (complications)
• Remission Induction
• Tadalafil
• Time Factors